Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 551-557

  Ozawa, Kazuhiro ^a   Minami, Hironobu ^b,c   Sato, Hitoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Docetaxel; Febrile neutropenia; Japanese cancer patients; Logistic regression analysis; Neutrophils

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COVARIANCE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; FEVER; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; NEUTROPENIA; TAXOIDS;

EID: 45849113322     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0648-8     Document Type: Article

References (20)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-339
2. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332
3. Smith GM, Leyland MJ, Farrell ID, Geddes AM (1988) A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother 21:647-655
4. Klastersky J (1993) Febrile neutropenia. Curr Opin Oncol 5:625-632
5. Rubenstein EB, Rolston KV (1995) Outpatient treatment of febrile neutropenic patients with cancer. Eur J Cancer 31A:2-4
6. Kojima A, Shinkai T, Soejima Y, Okamoto H, Eguchi K, Sasaki Y, Tamura T, Oshita F, Ohe Y, Saijo N (1994) A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am J Clin Oncol 17:400-404
7. Carlson JW, Fowler JM, Saltzman AK, Carter JR, Chen MD, Mitchell SK, Dunn D, Carson LF, Adcock LL, Twiggs LB (1994) Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecol Oncol 55(Pt 1):415-420
8. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35(8):1194-1201
9. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354-2362. Erratum in: J Clin Oncol. 2004 Jan 1 22(1): 209
10. Vasey PA (2003) Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 21(10 Suppl):136s-144s
11. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14(5):1672-1678
12. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70(2):380-383
13. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512
14. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196
15. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14(2):636-643
16. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 37(3-4):351-360
17. Ozawa K, Minami H, Sato H (2007) Population pharmacokinetic- pharmacodynamic analysis for the time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Sci 98:1985-1992
18. Vergniol J, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278
19. Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54-75
20. Harrell Jr FE, Lee KL, Mark DB (1996) Mulitvariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387